Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | ESMO 2021: key trials for breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses two big breast cancer trials from ESMO 2021: DESTINY-Breast03 (NCT03529110) and MONALEESA-2 (NCT01958021). DESTINY-Breast03 compared trastuzumab emtansine (T-DM1) to trastuzumab deruxtecan as a second-line therapy. The primary endpoint was met, with a significant improvement in progression free survival. Additionally, the incidence of adverse side effects was reduced compared to DESTINY-Breast01. MONALEESA-2 investigated ribociclib as a first-line treatment for HER2-negative, advanced breast cancer. The overall survival (OS) of these patients saw an improvement of 12.5 months, with OS increasing year-on-year in follow-ups. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.


Dr. Hamilton discloses research funding (payable to institution only, no personal funds) from: OncoMed, Genentech/Roche, Zymeworks, Rgenix, ArQule, Clovis, Silverback Therapeutics, Millenium, Acerta Pharma, Sermonix Pharmaceuticals, Torque, Black Diamond, Karyopharm, Infinity Pharmaceuticals, Curis, Syndax, Novartis, Boehringer Ingelheim, Immunomedics, FujiFilm, Taiho, Deciphera, Fochon, Molecular Templates, Onconova Therapeutics, Dana Farber Cancer Hospital, Hutchinson MediPharma, MedImmune, SeaGen, Puma Biotechnology, Compugen, TapImmune, Lilly, Pfizer, H3 Biomedicine, Takeda, Merus, Regeneron, Arvinas, StemCentRx, Verastem, eFFECTOR Therapeutics, CytomX, InventisBio, Lycera, Mersana, Radius Health, Abbvie, Nucana, Leap Therapeutics, Zenith Epigenetics, Harpoon, Orinove, AstraZeneca, Tesaro, Macrogenics, EMD Serono, Daiichi Sankyo, Syros, Sutro, G1 Therapeutics, Merck, PharmaMar, Olema, Polyphor, Immunogen, Plexxicon, Amgen, Akesobio Australia, Shattuck Labs.

D. Hamilton discloses consulting/advisory role payments (to institution only, no personal funds accepted) from: Genentech/Roche, Boehringer Ingelheim, Novartis, Dantari, Lilly, Merck, Puma Biotechnology, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo, AstraZeneca, Arvinas, Deciphera Pharmaceuticals, Eisai, Seagen.